文献速递肾移植

自动化微流控联合检测尿CCL2、CXCL9、CXCL10和VEGF-A用于肾移植受者监测

Combination Automated Microfluidics Measurement of Urine C-C Motif Ligand 2, CXC-Motif Chemokine 9, CXC-Motif Chemokine 10, and Vascular Endothelial Growth Factor A for Monitoring Patients with a Kidney Transplant.
PubMed 文献 · Clin J Am Soc Nephrol · 2025-03-11

该多中心观察性研究在517份训练集样本中开发联合四种尿生物标志物的风险算法,并在两个儿科队列(N=174)的三个实验室验证。结果显示该自动化平台60–70分钟出结果,score4鉴别急性排斥的特异性75%、阴性预测值92%,优于单独eGFR。

要点

  • 联合尿CCL2、CXCL9、CXCL10和VEGF-A可识别无活检证实的急性排斥的稳定移植受者,特异性>75%、阴性预测值94%。
  • 自动化平台60–70分钟出结果,三个独立站点结果可重复。
  • score4在稳定GFR患者的因症和监测活检中诊断性能优于任一单独生物标志物及eGFR。

核心结论

  • 自动化检测尿CCL2、CXCL9、CXCL10和VEGF-A可区分肾移植受者排斥低风险与高风险。
  • 该检测低成本、快速、不依赖操作者,可辅助移植后常规监测的临床决策。

研究设计与样本

  • 多中心观察性研究,训练集为517份成人及儿科受者在监测或指征肾活检时采集的库存样本。
  • 风险算法在训练集开发,并在两个额外儿科队列(N=174)的三个实验室站点验证。

主要发现

  • 训练集517份活检包括正常330份、急性排斥92份、临界排斥95份。
  • 每种生物标志物独立区分正常活检与急性排斥(P < 10−5)。
  • 联合四种标志物的score4在稳定GFR患者的因症和监测活检中诊断性能优于任何单个标志物及eGFR评估。
  • 验证队列中score4保持优异诊断性能,特异性75%、阴性预测值92%。

关键数值与推荐

  • 训练集每種生物标志物区分正常与急性排斥的P < 10−5。
  • 验证队列score4特异性75%、阴性预测值92%。

临床怎么用

  • 可用于移植后常规监测,辅助识别无需活检的稳定受者。
  • 自动化平台快速且不依赖操作者,适合多中心应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Combining urine C-C motif ligand 2, CXC-motif chemokine 9, CXC-motif chemokine 10, and vascular endothelial growth factor A identifies stable transplant recipients without biopsy-proven acute rejection with >75% specificity and 94% negative predictive value. Measuring four urine analytes in combination using an automated platform is highly efficient (<70 minutes) and reproducible across three independent sites. Automated urine analyte measurement provides critical decision support and outperforms eGFR measurements alone for post-transplantation monitoring. BACKGROUND: Recent studies indicate that up to 36% of pediatric and adult kidney transplant recipients with stable serum creatinine levels will have acute rejection detected on surveillance biopsy. The purpose of this study was to develop and validate a risk algorithm for identifying low- and high-risk patients using a novel automated platform that simultaneously measures urinary C-C motif ligand 2 (CCL2), CXC-motif chemokine 9 (CXCL9), CXC-motif chemokine 10 (CXCL10), and vascular endothelial growth factor A (VEGF-A) with high precision. METHODS: We designed a multicenter observational study to evaluate the performance of urinary CCL2, CXCL9, CXCL10, and VEGF-A in a training set of 517 banked samples collected at the time of surveillance or indication kidney biopsies from both adult and pediatric recipients. Risk algorithms combining all four analytes were developed in the training set and subsequently validated in three laboratory sites in two additional pediatric cohorts (N=174). RESULTS: The automated platform had remarkably high throughput, generating reproducible results in 60–70 minutes. Analysis was initially performed in the training set (N=517), which included biopsies read as normal (N=330), acute rejection (N=92), or borderline rejection (N=95). We found that each biomarker independently discriminated normal biopsies versus those with acute rejection (P < 10−5). A risk algorithm using all four biomarkers (score4) had excellent diagnostic performance for acute rejection in both for-cause and surveillance biopsies performed on patients with stable GFRs, outperforming any individual biomarker as well as estimated GFR assessments. Validation assays performed in the two additional pediatric cohorts in three laboratory sites demonstrated a robust correlation of results; score4 retained excellent diagnostic performance (75% specificity and 92% negative predictive value). CONCLUSIONS: Automated measurements of urine CCL2, CXCL9, CXCL10, and VEGF-A can distinguish kidney transplant recipients at low versus high risk of rejection. We suggest that this assay can advantage clinical decision making in routine post-transplant monitoring because of its low cost, rapid throughput, and operator independence.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Seifert ME, Kho AT, Sheward L, et al. Combination Automated Microfluidics Measurement of Urine C-C Motif Ligand 2, CXC-Motif Chemokine 9, CXC-Motif Chemokine 10, and Vascular Endothelial Growth Factor A for Monitoring Patients with a Kidney Transplant. Clin J Am Soc Nephrol. 2025. PMID: 40067364. doi:10.2215/CJN.0000000666

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。